So, news came out last week that the UK’s National Health Service will not be providing Ocrevus for treating primary progressive MS (PPMS) in England*. But, panic not, the decision is far from being set in stone. Why is this? Because the decision by the National Institute for Health and Care Excellence, (NICE), was … Continue reading Ocrevus blocked again, this time for PPMS, as not cost-effective
cost-effective
Threat to three DMTs removed after manufacturers cut prices
Manufacturers of three relapsing multiple sclerosis drugs have cut prices to remain available to Britain's National Health Service (NHS). They are all diseases modifying therapies (DMTs). In January, I brought you news that five such drugs were under threat, having been found to be not cost-effective as long-term therapy options. In a draft recommendation from … Continue reading Threat to three DMTs removed after manufacturers cut prices
50shadesofsun 